Jazz Pharmaceuticals Acquires Chimerix for About $935 Million
March 5, 2025
Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire Chimerix in an all-cash transaction valued at approximately $935 million (about $8.55 per share). The deal is expected to close in the second quarter of 2025, pending customary closing conditions, including tender of shares in a tender offer.
- Buyers
- Jazz Pharmaceuticals plc
- Targets
- Chimerix
- Industry
- Pharmaceuticals
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.